Characteristics of rheumatoid arthritis patients with concomitant hepatitis C virus infection

Mahmoud, Geilan A.; Zayed, Hania S.; Sherif, M. M.; Mostafa, Mervat

doi:10.1016/j.ejr.2011.05.003

Cited by 7 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47 48 Although HCV-induced inflammatory arthritis can present as polyarticular, symmetrical arthritis and positive rheumatoid factor, which mimic RA or meet the diagnosis of RA, it is generally less aggressive, non-nodular, non-deforming, non-erosive and negative for antibodies against anti-CCP in comparison to RA. 49 Moreover, there was no statistically significant difference in the frequency of erosive arthritis or anti-CCP positivity between patients with HCV-antibody-positive and HCV-antibody-negative RA. 49 Thus, anti-CCP is a reliable test to distinguish RA from HCV-induced inflammatory arthritis in addition to X-ray findings.…”

Section: Discussionmentioning

confidence: 81%

“… 49 Moreover, there was no statistically significant difference in the frequency of erosive arthritis or anti-CCP positivity between patients with HCV-antibody-positive and HCV-antibody-negative RA. 49 Thus, anti-CCP is a reliable test to distinguish RA from HCV-induced inflammatory arthritis in addition to X-ray findings. 46 Together, these findings provide a theoretical basis and support the hypothesis that it is truly RA rather than HCV-associated inflammatory arthritis in the present study.…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database

Tung

Lai

et al. 2018

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo illuminate the association between interferon-based therapy (IBT) and the risk of rheumatoid arthritis (RA) in patients infected with hepatitis C virus (HCV).Design, setting, participants and interventionsThis retrospective cohort study used Taiwan’s Longitudinal Health Insurance Database 2005 that included 18 971 patients with HCV infection between 1 January 1997 and 31 December 2012. We identified 1966 patients with HCV infection who received IBT (treated cohort) and used 1:4 propensity score-matching to select 7864 counterpart controls who did not receive IBT (untreated cohort).Outcome measuresAll study participants were followed until the end of 2012 to calculate the incidence rate and risk of incident RA.ResultsDuring the study period, 305 RA events (3.1%) occurred. The incidence rate of RA was significantly lower in the treated cohort than the untreated cohort (4.0 compared with 5.5 per 1000 person-years, p<0.018), and the adjusted HR remained significant at 0.63 (95% CI 0.43 to 0.94, p=0.023) in a Cox proportional hazards regression model. Multivariate stratified analyses revealed that the attenuation in RA risk was greater in men (0.35; 0.15 to 0.81, p=0.014) and men<60 years (0.29; 0.09 to 0.93, p=0.036).ConclusionsThis study demonstrates that IBT may reduce the risk of RA and contributes to growing evidence that HCV infection may lead to development of RA.

show abstract

Section: Discussionmentioning

confidence: 81%